Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

Relmada Therapeutics Inc (RLMD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Relmada Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.625 -0.015    -2.34%
29/07 - Closed. Currency in USD
After Hours
0.625
0.000
0.000%
23:32:46 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 52,749
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.604 - 0.644
Relmada Therapeutics 0.625 -0.015 -2.34%

Relmada Therapeutics Inc Company Profile

 
Get an in-depth profile of Relmada Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

17

Equity Type

ORD

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Contact Information

Address 2222 Ponce de Leon Blvd. Floor 3
Coral Gables, 33134
United States
Phone 786 629 1376
Fax -

Top Executives

Name Age Since Title
Paul E. Kelly 68 2015 COO & Director
Maged S. Shenouda 61 2020 Chief Financial Officer
John Glasspool 62 2019 Independent Director
Sergio Traversa 65 2012 CEO & Director
Charles J. Casamento 80 2015 Independent Chairman of the Board
Fabiana Fedeli 54 2023 Independent Director
Paolo Manfredi 62 2020 Member of Scientific Advisory Board
Stephen M. Stahl - 2020 Member of Scientific Advisory Board
Dan Iosifescu - 2020 Member of Scientific Advisory Board
Sanjay Johan Mathew - 2020 Member of Scientific Advisory Board
Charles E. Inturrisi - - Member of Scientific Advisory Board
Yair Lotan - 2025 Chairman of Clinical Advisory Board
Thomas P. Laughren - 2020 Member of Scientific Advisory Board
Maurizio Fava - 2017 Member of Scientific Advisory Board
Marco Pappagallo 66 2020 Member of Scientific Advisory Board
Luca Pani - 2020 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RLMD Comments

Write your thoughts about Relmada Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email